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Abstract
Background: Serum uric acid (SUA) is associated with left ventricular hypertrophy in a wide spectrum of study
population. However, whether this association exists in patients with hypertrophic cardiomyopathy (HCM, including
obstructive HCM), and if present, whether gender has any impact on this association, remains unknown.
Methods: A total of 161 patients with obstructive HCM (age 47.2 ± 10.8 years, 99 (62 %) men) were included in this
study. All patients underwent extensive clinical, laboratory, echocardiographic, and cardiac magnetic resonance
(CMR) imaging examinations. Left ventricular mass index (LVMI) was assessed using CMR.
Results: The mean value of SUA was 353.4 ± 87.5 μmol/L. Both SUA levels (381.2 ± 86.4 vs. 309.0 ± 69.3 μmol/L, p < 0.001)
and LVMI (96.2 ± 32.1 vs. 84.4 ± 32.4 g/m2, p = 0.025) were significantly higher in men than in women. LVMI increased
progressively across sex-specific tertiles of SUA in women (p= 0.030), but not in men (p = 0.177). SUA was positively
correlated with LVMI in female patients (r = 0.372, p = 0.003), but not in males (r = 0.112, p = 0.269). On multivariate linear
regression analysis, SUA was independently associated with LVMI in females (β = 0.375, p = 0.002), but not in males.
Conclusions: SUA levels are significantly and independently associated with LVMI in women with obstructive HCM, but
not in men. Our findings imply the potential significance of urate-lowering regimens in female patients with obstructive
HCM.
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Background
Serum uric acid (SUA), as an end metabolite of purine
degradation, is associated with multiple established car-
diovascular risk factors, including hypertension, diabetes
mellitus, dyslipidemia, obesity, and metabolic syndrome
[1–5]. Although its importance in cardiovascular condi-
tions remains controversial [6], elevated SUA has been
shown to be an independent predictor for the incidence
and adverse cardiovascular outcomes of coronary heart
disease, myocardial infarction, heart failure, stroke, atrial
fibrillation, and chronic kidney disease (CKD) [7–12].
Baseline SUA levels are also related to an increased risk
for cardiovascular and all-cause mortality in the general
population [13]. Multiple studies, although not all, have
demonstrated that SUA levels are significantly and inde-
pendently associated with left ventricular hypertrophy
(LVH) and left ventricular mass index (LVMI) in the
general population and in patients with essential hyper-
tension, CKD, and renal transplant [14–24]. Moreover,
divergent sex differences in the relationship between
SUA and LVH have been observed. Some studies found
this relationship only present in males [14, 16, 18, 25],
while others only in females [17, 20, 22].
Hypertrophic cardiomyopathy (HCM) is a common
inherited heart disease, mainly with an autosomal
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dominant pattern, and caused by more than 1500 indi-
vidual mutations in 11 or more genes encoding cardiac
sarcomere proteins [26, 27]. It can lead to heterogeneous
clinical presentations, ranging from asymptomatic status
with normal longevity to progressive heart failure, atrial
fibrillation with risk for embolic stroke, and sudden
death [27, 28]. HCM is characterized by unexplained
LVH, as well as myocyte disarray, replacement fibrosis,
and small vessel disease [29]. Quite recently, uric acid
has been reported to be independently associated with
adverse prognosis in patients with HCM [30]. However,
the pathophysiological mechanisms underlying this asso-
ciation have not been elucidated. There are scanty data
regarding the relationship between SUA and LVH in pa-
tients with HCM [30]. In addition, it is well known that
the majority of HCM patients (about 70 %) have left
ventricular outflow tract (LVOT) obstruction present at
rest or with physiologic exercise [31]. Accordingly, the
aim of our study was to examine in patients with ob-
structive HCM the association between SUA and LVMI
(as assessed by cardiac magnetic resonance (CMR) im-




Between November 2008 and August 2013, consecutive
patients with obstructive HCM who were referred to
Fuwai Hospital (Beijing, China) for a comprehensive car-
diac evaluation were enrolled in this study. HCM was di-
agnosed by an otherwise unexplained increase in left
ventricular wall thickness (≥15 or ≥13 mm with a definite
family history of HCM), as determined with echocardiog-
raphy or CMR [26]. LVOT obstruction was considered as
a peak instantaneous LVOT pressure gradient ≥30 mmHg
at rest or during physiological provocation such as Val-
salva maneuver, standing, and exercise [26]. A complete
evaluation was performed in each enrolled patient, includ-
ing demographic characteristics, medical history, physical
examination, 12-lead electrocardiography (ECG), 24-h
ambulatory ECG monitoring, transthoracic echocardiog-
raphy (TTE), routine blood tests, CMR, and coronary
angiography. Patients with the following conditions were
excluded from the present study: significant coronary ar-
tery disease (epicardial coronary stenosis >70 % on coron-
ary angiography, previous myocardial infarction, bypass
surgery, or percutaneous coronary intervention), valvular
heart disease, left ventricular ejection fraction (LVEF)
<50 % as measured by echocardiography or CMR, cere-
brovascular disease, renal dysfunction (defined as an esti-
mated glomerular filtration rate (eGFR) <60 mL/min/
1.73 m2), gout, concomitant neoplasm, infection, connect-
ive tissue disease, pregnancy, or breast feeding. None of
the included patients were receiving any urate-lowering
agents. Patients with a history of alcohol septal ablation,
septal myectomy, or permanent mechanical device im-
plantation were also excluded. Eventually, 161 patients
were included in the current study.
The study protocol was approved by the Ethics Com-
mittee of Fuwai Hospital and conducted in accordance
with the Declaration of Helsinki. All patients gave their
written informed consent.
Echocardiography
TTE was performed by an experienced cardio-sonographer
using the Phillips iE33 Color Doppler Ultrasound System
(Philips Healthcare, Andover, MA, USA). M-mode, two-
dimensional, and pulsed and continuous-wave Doppler
studies were utilized in the standard evaluation according
to the guidelines of the American Society of Echocardiog-
raphy [32]. All patients underwent resting LVOT gradient
measurements with continuous-wave Doppler echocardiog-
raphy, while LVOT gradient after provocation was only de-
termined in those with a resting LVOT gradient
<50 mmHg. The severity of mitral regurgitation (MR),
graded from mild to severe in accordance with European
association of echocardiography criteria, was evaluated
semi-quantitatively using color Doppler flow imaging [33].
CMR protocol and image analysis
CMR imaging was performed on a 1.5-T scanner
(Magnetom Avanto, Siemens Medical Solutions, Erlangen,
Germany) with electrocardiographic gating and breath
holding, as described in detail previously [34, 35]. Briefly,
cine images were obtained by a true fast imaging with
steady-state precession (TrueFisp) sequence, in left ven-
tricular (LV) two-chamber and four-chamber long-axis
views, LVOT view, and LV short-axis views (contiguous
slices from the apex to base for the full coverage of LV).
The following imaging parameters were used: slice thick-
ness 6 mm, repetition time 2.7 ms, echo time 1.2 ms, field
of view 360 × 315 mm2, flip angle 70°, temporal resolution
40 ms, and image matrix 192 × 162.
All CMR images were analyzed off-line by an experi-
enced radiologist, using dedicated software (version
VE36A, ARGUS, Siemens, Germany) for image analysis.
The LV endocardial and epicardial contours were manu-
ally planimetried at end diastole and end systole on each
short-axis slice, taking special care to exclude the papillary
muscles from the total myocardial mass. LV volumes,
LVEF, and LV mass (LVM) were then derived in a stand-
ard manner. LVM was calculated from the LV myocardial
volume (measured at end diastole) multiplied by the
specific gravity of myocardium (1.05 g/mL). All of those
measurements were indexed to body surface area (BSA) in
square meter, except LVEF. The LV end-diastolic diameter
(LVEDD) and maximal wall thickness were determined on
the short-axis cine images at end diastole.
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Biochemical measurements
Venous blood samples were taken in the early morning
after an overnight fast, within 2 days of TTE and 1 week
of CMR examination. All of those samples were sent to
the clinical laboratory of Fuwai hospital immediately and
analyzed by medical technologists who were unaware of
any clinical information about the study patients. Serum
levels of creatinine, uric acid, total cholesterol (TC), triglyc-
erides (TG), high-density lipoprotein cholesterol (HDL-C),
low-density lipoprotein cholesterol (LDL-C), fasting
blood glucose (FBG), and high-sensitivity C-reactive
protein (hs-CRP) were measured by routine laboratory
methods using an Olympus AU-5400 auto-analyzer
(Olympus Corporation, Mishama, Japan). SUA concentra-
tions were determined using the uricase colorimetric assay
(Uric Acid Kit, Biosino, Beijing, China). Plasma levels of
N-terminal pro-B-type natriuretic peptide (NT-proBNP)
were also measured, with an electrochemiluminescent im-
munoassay (Elecsys proBNP II assay, Roche Diagnostics
GmbH, Mannheim, Germany) on a Cobas 6000 analyzer
(Roche Diagnostics). The eGFR (mL/min/1.73 m2) was
calculated using the Chronic Kidney Disease Epidemi-
ology Collaboration (CKD-EPI) equation [36]. Dyslipid-
emia was defined as those with serum LDL-C
≥3.37 mmol/L, TG ≥1.70 mmol/L, HDL-C <1.04 mmol/L,
or the use of lipid-lowering drugs.
Statistical analysis
Continuous variables are presented as either mean ±
standard deviation (SD) or median (interquartile range
(IQR)), according to their distribution. Categorical vari-
ables are shown as frequencies (percentages). Differences
of continuous variables were assessed with the inde-
pendent Student’s t test, Mann–Whitney U test, one-
way analysis of variance (followed by the Dunnett’s t
test for multiple comparisons) or Kruskal–Wallis H
test (as appropriate). Categorical variables were com-
pared using the χ2 test or Fisher’s exact test (as appropri-
ate). The simple correlation between two continuous
variables was examined using the Pearson or Spearman
correlation test (as appropriate). To evaluate if SUA was
an independent risk factor for LVMI in our patients with
obstructive HCM, stepwise multiple linear regression ana-
lysis (p value threshold to enter ≤0.05; to remove, ≤0.10)
was applied by adjusting for potential confounding factors
affecting LVMI. All data analyses were undertaken using
the statistical package SPSS 21.0 (SPSS Inc, Chicago, IL,
USA). A two-tailed p < 0.05 was considered statistically
significant.
Results
The mean age of the 161 obstructive HCM patients was
47.2 ± 10.8 years (range, 20–71 years), and there were 99
males and 62 females. Most (86 %) of them had moderate
or severe dyspnea (NYHA functional class III/IV). Mean
resting LVOT gradient was 78.6 ± 32.4 mmHg. The con-
centrations of SUA ranged from 155.9 to 648.1 μmol/L
(mean, 353.4 ± 87.5 μmol/L). The demographic and clin-
ical parameters of those patients, analyzed on the
basis of gender, are presented in Table 1. Men were
younger (45.4 ± 10.0 vs. 50.1 ± 11.5 years, p = 0.008)
and more likely to smoke (58 vs. 3 %, p < 0.001) than
women. As expected, SUA levels (381.2 ± 86.4 vs.
309.0 ± 69.3 μmol/L, p < 0.001) and LVMI (96.2 ± 32.1
vs. 84.4 ± 32.4 g/m2, p = 0.025) were significantly
higher in men than in women. In addition, compared
with women, men had significantly higher body mass
index (BMI), left ventricular end-diastolic diameter
(LVEDD) and LVM, and lower levels of HDL-C and NT-
proBNP. The values of eGFR (101.7 ± 12.8 vs. 99.8 ±
14.6 mL/min/1.73 m2, p = 0.386) were comparable be-
tween the two genders, although serum creatinine (77.2 ±
11.3 vs. 60.1 ± 11.2 μmol/L, p < 0.001) was greater in men
than in women.
The demographic and clinical data of the study patients
on the basis of sex-specific tertiles of SUA are reported in
Table 2. In male patients, BMI (p = 0.022), serum TG
(p = 0.001), and left atrial (LA) diameter (p = 0.025)
increased significantly with ascending SUA tertiles.
Men in the third tertile had significantly lower resting
LVOT gradient than those in the second tertile (p < 0.05).
Compared with the first and second tertiles, the preva-
lence of resting LVOT gradient ≥30 mmHg was signifi-
cantly lower in the third tertile (p = 0.003). Of note,
LVMI did not differ significantly across SUA tertiles
in men (p = 0.177), whereas it did show a progressive
increase with growing tertiles of SUA in women (p =
0.030, Fig. 1). There were no significant differences
with respect to age, eGFR, hs-CRP, NT-proBNP,
medications taken (including loop and thiazide di-
uretics), maximal wall thickness (MWT), LVM and
the prevalence of hypertension, diabetes mellitus,
smoking, and dyslipidemia among the SUA tertiles in both
sexes. BMI (p = 0.820), resting LVOT gradient (p = 0.398),
and the percentage of menopause (p = 0.863) were similar
across tertiles of SUA in females.
In males, SUA was positively correlated with BMI
(r = 0.309, p = 0.002), TG (r = 0.343, p = 0.001), hs-CRP
(r = 0.198, p = 0.049), and LA diameter (r = 0.247, p =
0.014), while negatively with HDL-C (r = −0.259, p =
0.010; Table 3). No significant correlations were found
between SUA and LVM (r = 0.144, p = 0.155) and
LVMI (r = 0.112, p = 0.269; Fig. 2) in men. In females,
SUA was significantly associated with hs-CRP (r = 0.264,
p = 0.038), LA diameter (r = 0.277, p = 0.029), LVM (r =
0.330, p = 0.009), and LVMI (r = 0.372, p = 0.003; Fig. 2).
In addition, there were no significant correlations between
SUA levels and age, blood pressures, eGFR, TC, fasting
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Table 1 Demographic and clinical characteristics of the obstructive hypertrophic cardiomyopathy patients according to gender
Variable Male (n = 99) Female (n = 62) p value
Age (years) 45.4 ± 10.0 50.1 ± 11.5 0.008
Body mass index (kg/m2) 26.3 ± 3.4 24.6 ± 3.0 0.004
Hypertension 26 (26 %) 22 (36 %) 0.213
Diabetes mellitus 5 (5 %) 1 (2 %) 0.488
Dyslipidemia 32 (32 %) 15 (24 %) 0.27
Current smokers 57 (58 %) 2 (3 %) <0.001
Duration of obstructive HC (months) 12 (2–48) 12 (2–48) 0.729
NYHA functional class 0.636
I 4 (4 %) 5 (8 %)
II 10 (10 %) 4 (7 %)
III 71 (72 %) 41 (66 %)
IV 14 (14 %) 12 (19 %)
Syncope 30 (30 %) 23 (37 %) 0.372
Family history of HC 20 (20 %) 16 (26 %) 0.406
Family history of sudden death 11 (11 %) 6 (10 %) 0.773
Systolic blood pressure (mmHg) 117.2 ± 16.1 117.5 ± 19.3 0.902
Diastolic blood pressure (mmHg) 73.8 ± 11.1 71.6 ± 11.2 0.226
Heart rate (beats/min) 68.6 ± 9.9 70.8 ± 12.8 0.252
Atrial fibrillation 7 (7 %) 6 (10 %) 0.555
Non-sustained ventricular tachycardiaa 4 (5 %) 5 (10 %) 0.433
Medications
Beta-blockers 79 (80 %) 45 (73 %) 0.289
Calcium antagonists 26 (26 %) 25 (40 %) 0.062
Amiodarone 5 (5 %) 2 (3 %) 0.877
ACEI/ARB 11 (11 %) 14 (23 %) 0.051
Statins 10 (10 %) 8 (13 %) 0.583
Aspirin 25 (25 %) 15 (24 %) 0.880
Diuretics 4 (4 %) 5 (8 %) 0.466
Laboratory data
Serum creatinine (μmol/L) 77.2 ± 11.3 60.1 ± 11.2 <0.001
eGFR (mL/min/1.73 m2) 101.7 ± 12.8 99.8 ± 14.6 0.386
Blood glucose (mmol/L) 4.85 ± 0.59 4.85 ± 0.62 0.978
HbA1c (%) 5.59 ± 0.53 5.60 ± 0.52 0.993
Total cholesterol (mmol/L) 4.62 ± 1.01 4.54 ± 1.00 0.604
HDL cholesterol (mmol/L) 1.07 ± 0.25 1.26 ± 0.30 <0.001
LDL cholesterol (mmol/L) 2.89 ± 0.92 2.76 ± 0.75 0.380
Triglycerides (mmol/L) 1.69 ± 0.93 1.52 ± 0.83 0.251
hs-CRP (mg/L) 1.25 (0.60–2.14) 0.96 (0.40–1.94) 0.318
NT-proBNP (pmol/L) 1154.1 (775.5–1692.5) 1811.9 (869.6–2816.0) 0.002
Serum uric acid (μmol/L) 381.2 ± 86.4 309.0 ± 69.3 <0.001
Echocardiography
Systolic anterior motion 94 (95 %) 58 (94 %) 0.981
Moderate or severe mitral regurgitation 36 (36 %) 25 (40 %) 0.614
LVOTG at rest (mmHg) 77.9 ± 32.5 79.7 ± 32.5 0.735
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blood glucose (FBG), glycated hemoglobin (HbA1c), NT-
proBNP, LVOT gradient (at rest or after provocation),
MWT, or LVEF in each gender group.
SUA concentrations were similar between smokers
and non-smokers in both men and women (data not
shown). Additionally, SUA levels did not differ between
patients with and without hypertension, diabetes melli-
tus, or dyslipidemia, in either male or female subgroups.
Likewise, the use of loop or thiazide diuretics, as well as
angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers, did not affect SUA concentrations in
both genders. In females, there were no significant dif-
ferences in SUA levels between patients with menopause
(n = 31) and those without (n = 31; 312.9 ± 66.9 vs. 305.1
± 72.6 μmol/L, p = 0.665).
Multiple linear regression analysis was performed to
determine whether the correlations between SUA and
LVMI observed in females on univariate analysis were
still significant after controlling for potential confounding
factors affecting LVMI. In females, SUA was independently
associated with LVMI (β = 0.375, p = 0.002), after adjust-
ment for age, menopause, BMI, hypertension, diabetes mel-
litus, dyslipidemia, smoking, eGFR, usage of ACEI/ARB,
usage of diuretics, hs-CRP, duration of obstructive HCM,
and resting LVOT gradient (Table 4). In addition, resting
LVOT gradient was also independently associated with
LVMI in women (β = 0.320, p = 0.007). However, on mul-
tiple linear regression analysis including the same covari-
ables (except menopause) as in females, no variables were
entered into the equation for males. Moreover, replacing
hypertension with systolic and diastolic blood pressures,
diabetes mellitus with FBG or HbA1c, dyslipidemia with
TC, TG, LDL-C, and HDL-C, and eGFR with serum cre-
atinine in those models did not materially alter the inde-
pendent associations between SUA and LVMI in women
(β = 0.345, p = 0.003). Similarly, not any covariates were in-
dependently related to LVMI in men.
Discussion
A large body of evidence suggests that SUA levels are
significantly related to LVH and LVMI in different study
populations, including patients with essential hyperten-
sion, CKD and renal transplant, and the general popula-
tion. Iwashima et al. demonstrated that SUA was
independently associated with LVMI in 619 hypertensive
patients [21]. Moreover, they also showed that hyperuri-
cemia combined with LVH was an independent and
powerful predictor for cardiovascular disease, including
myocardial infarction, angina pectoris, congestive heart
failure, cerebral infarction, and transient cerebral ische-
mia. In a total of 540 patients with CKD, SUA was posi-
tively correlated with LVMI [23], which was further
validated in female CKD patients of another study [22].
After adjustment for potential confounding factors, a
significant and independent relationship between SUA
and LVMI was observed in renal transplant recipients
[24]. In a general population of 3305 males, the preva-
lence of LVH diagnosed by electrocardiography was in-
dependently associated with SUA concentration [14].
Recently, Zhu et al. reported that MWT increased
Table 1 Demographic and clinical characteristics of the obstructive hypertrophic cardiomyopathy patients according to gender
(Continued)
LVOTG after provocation (mmHg)b 95.7 ± 28.9 87.8 ± 15.8 0.312
LVOTG at rest ≥30 mmHg 93 (94 %) 57 (92 %) 0.865
Cardiac magnetic resonance
Left atrium diameter (mm) 39.8 ± 7.6 40.7 ± 7.9 0.483
LV end-diastolic diameter (mm) 46.4 ± 4.1 44.7 ± 4.1 0.010
Maximum wall thickness (mm) 23.5 ± 4.4 23.0 ± 5.4 0.543
Maximum wall thickness ≥30 mm 8 (8 %) 5 (8 %) 0.997
LV ejection fraction (%) 72.2 ± 7.2 72.0 ± 7.3 0.893
LV mass (g) 180.6 ± 64.9 137.4 ± 53.3 <0.001
LV end-diastolic volume index (mL/m2) 65.1 ± 14.1 63.9 ± 13.9 0.61
LV end-systolic volume index (mL/m2) 18.1 ± 6.1 18.1 ± 7.0 0.976
Stroke volume index (mL/m2) 47.0 ± 11.3 45.8 ± 9.6 0.496
Cardiac index (L/min/m2) 3.12 ± 0.77 3.13 ± 0.81 0.925
LV mass index (g/m2) 96.2 ± 32.1 84.4 ± 32.4 0.025
Data are expressed as mean ± SD, number (percentage), or median (interquartile range)
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, HC hypertrophic
cardiomyopathy, HDL high-density lipoprotein, hs-CRP high-sensitivity C-reactive protein, LDL low-density lipoprotein, LV left ventricular, LVOTG left ventricular outflow tract
gradient, NT-proBNP N-terminal pro-B-type natriuretic peptide, NYHA New York Heart Association
aAmbulatory 24-h Holter monitoring results were available in 127 of the 161 study patients
bLVOTG was provoked in 50 of the 161 study patients
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Serum uric acid range (μmol/L) <342.7 342.7–410.8 ≥410.8 <266.3 266.3–328.2 ≥328.2
Age (years) 45.2 ± 10.1 45.9 ± 10.8 45.2 ± 9.4 0.959 48.5 ± 12.9 50.9 ± 9.4 50.8 ± 12.5 0.755
Body mass index
(kg/m2)
25.1 ± 3.5 26.0 ± 3.3 27.4 ± 2.9 0.022 25.0 ± 3.0 24.4 ± 2.6 24.5 ± 3.4 0.820
Menopause – – – – 9 (45 %) 11 (52 %) 11 (52 %) 0.863
Hypertension 8 (24 %) 11 (33 %) 7 (21 %) 0.508 6 (30 %) 8 (38 %) 8 (38 %) 0.824
Diabetes mellitus 3 (9 %) 0 (0 %) 2 (6 %) 0.365 0 (0 %) 1 (5 %) 0 (0 %) 1.000
Dyslipidemia 8 (24 %) 10 (30 %) 14 (42 %) 0.274 3 (15 %) 5 (24 %) 7 (33 %) 0.408
Current smokers 18 (55 %) 18 (55 %) 21 (64 %) 0.689 0 (0 %) 1 (5 %) 1 (5 %) 1.000
Duration of obstructive HC (months) 7 (1.5–42) 12 (2–66) 12 (1.5–60) 0.435 12 (1.25–36) 12 (1.5–24) 12 (3–72) 0.562
NYHA class III/IV 27 (82 %) 30 (91 %) 28 (85 %) 0.672 16 (80 %) 19 (91 %) 18 (86 %) 0.610
Syncope 10 (30 %) 8 (24 %) 12 (36 %) 0.563 6 (30 %) 7 (33 %) 10 (48 %) 0.459
Family history of HC 8 (24 %) 9 (27 %) 3 (9 %) 0.143 8 (40 %) 4 (19 %) 4 (19 %) 0.212
Family history of sudden death 5 (15 %) 4 (12 %) 2 (6 %) 0.614 4 (20 %) 0 (0 %) 2 (10 %) 0.073
Systolic blood pressure (mmHg) 119.8 ± 16.9 118.3 ± 17.7 113.5 ± 13.2 0.256 114.5 ± 13.5 120.5 ± 20.7 117.5 ± 22.9 0.616
Diastolic blood pressure (mmHg) 73.9 ± 10.9 74.8 ± 12.5 72.7 ± 9.9 0.742 69.3 ± 8.6 75.1 ± 12.9 70.4 ± 11.1 0.257
Heart rate (beats/min) 67.8 ± 9.5 69.1 ± 10.6 68.8 ± 9.7 0.861 72.4 ± 14.1 66.6 ± 8.7 73.5 ± 14.4 0.147
Atrial fibrillation 0 (0 %) 3 (9 %) 4 (12 %) 0.156 2 (10 %) 1 (5 %) 3 (14 %) 0.682
Non-sustained ventricular tachycardiaa 2 (8 %) 1 (4 %) 1 (4 %) 0.836 1 (6 %) 1 (6 %) 3 (21 %) 0.414
Medications
Beta-blockers 26 (79 %) 30 (91 %) 23 (70 %) 0.098 14 (70 %) 18 (86 %) 13 (62 %) 0.213
Calcium antagonists 12 (36 %) 10 (30 %) 4 (12 %) 0.066 5 (25 %) 9 (43 %) 11 (52 %) 0.194
Amiodarone 2 (6 %) 1 (3 %) 2 (6 %) 1.000 0 (0 %) 1 (5 %) 1 (5 %) 1.000
ACEI/ARB 6 (18 %) 2 (6 %) 3 (9 %) 0.370 4 (20 %) 4 (19 %) 6 (29 %) 0.801
Statins 2 (6 %) 6 (18 %) 2 (6 %) 0.208 1 (5 %) 3 (14 %) 4 (19 %) 0.508
Aspirin 5 (15 %) 9 (27 %) 11 (33 %) 0.223 6 (30 %) 3 (14 %) 6 (29 %) 0.498
Diuretics 0 (0 %) 3 (9 %) 1 (3 %) 0.320 2 (10 %) 1 (5 %) 2 (10 %) 0.864
Laboratory data
Serum creatinine (μmol/L) 73.7 ± 12.1 79.5 ± 10.0 78.4 ± 11.2 0.089 59.1 ± 12.5 59.9 ± 12.8 61.3 ± 8.5 0.824
eGFR (mL/min/1.73 m2) 104.4 ± 11.1 99.7 ± 13.6 101.2 ± 13.3 0.313 101.5 ± 17.0 98.5 ± 13.7 99.6 ± 13.4 0.805













Table 2 Demographic and clinical characteristics of the obstructive hypertrophic cardiomyopathy patients according to gender-specific tertiles of serum uric acid (Continued)
HbA1c (%) 5.56 ± 0.40 5.55 ± 0.54 5.68 ± 0.63 0.528 5.45 ± 0.26 5.69 ± 0.78 5.64 ± 0.35 0.316
Total cholesterol (mmol/L) 4.34 ± 0.73 4.68 ± 1.18 4.85 ± 1.03 0.108 4.21 ± 0.89 4.76 ± 0.96 4.62 ± 1.09 0.186
HDL cholesterol
(mmol/L)
1.13 ± 0.24 1.07 ± 0.28 1.01 ± 0.20 0.144 1.26 ± 0.37 1.23 ± 0.21 1.29 ± 0.32 0.814
LDL cholesterol
(mmol/L)
2.61 ± 0.71 3.00 ± 1.04 3.05 ± 0.95 0.102 2.43 ± 0.71 2.94 ± 0.77 2.90 ± 0.70 0.056



























Serum uric acid (μmol/L) 292.5 ± 42.8 373.3 ± 19.1 477.6 ± 54.0 <0.001 236.4 ± 22.0 298.2 ± 13.0 388.9 ± 44.0 <0.001
Echocardiography
Systolic anterior motion 30 (91 %) 33 (100 %) 31 (100 %) 0.365 18 (90 %) 20 (95 %) 20 (95 %) 0.684
Moderate or severe MR 13 (39 %) 12 (36 %) 11 (33 %) 0.877 10 (50 %) 7 (33 %) 8 (38 %) 0.536
LVOTG at rest (mmHg) 78.1 ± 27.5 89.7 ± 34.4 66.0 ± 31.6 0.011 81.3 ± 33.5 85.7 ± 32.1 72.2 ± 32.1 0.398
LVOTG at rest ≥30 mmHg 33 (100 %) 33 (100 %) 27 (82 %) 0.003 18 (90 %) 20 (95 %) 19 (91 %) 0.864
LVOTG after provocation (mmHg)b 96.2 ± 35.9 98.9 ± 21.6 91.7 ± 30.2 0.843 90.6 ± 8.0 88.3 ± 20.7 85.6 ± 18.8 0.877
Cardiac magnetic resonance
Left atrium diameter (mm) 37.8 ± 6.6 39.1 ± 8.3 42.6 ± 7.2 0.025 39.6 ± 8.6 38.8 ± 6.5 43.8 ± 8.0 0.088
LV end-diastolic diameter (mm) 46.8 ± 3.6 46.2 ± 5.2 46.3 ± 3.4 0.828 45.1 ± 4.5 45.6 ± 3.8 43.4 ± 3.9 0.213
Maximum wall thickness (mm) 23.1 ± 3.6 24.3 ± 5.6 23.0 ± 3.6 0.449 23.1 ± 3.5 21.9 ± 4.3 24.0 ± 7.4 0.429
Maximum wall thickness ≥30 mm 1 (3 %) 5 (15 %) 2 (6 %) 0.266 1 (5 %) 1 (5 %) 3 (14 %) 0.605
LV ejection fraction (%) 71.5 ± 7.5 72.7 ± 4.6 72.4 ± 8.9 0.775 72.1 ± 7.8 71.2 ± 7.1 72.7 ± 7.3 0.805
LV mass (g) 162.5 ± 45.2 194.4 ± 77.8 185.0 ± 65.2 0.122 117.6 ± 37.5 136.6 ± 50.5 157.0 ± 63.0 0.058
LV end-diastolic volume index (mL/m2) 65.2 ± 12.3 66.2 ± 15.1 63.9 ± 15.1 0.797 60.1 ± 10.0 69.8 ± 16.4 61.8 ± 13.0 0.053
LV end-systolic volume index (mL/m2) 18.7 ± 6.7 17.9 ± 4.6 17.7 ± 7.0 0.786 16.9 ± 7.3 20.4 ± 7.6 16.9 ± 5.8 0.177
Stroke volume index (mL/m2) 46.5 ± 9.4 48.3 ± 12.0 46.2 ± 12.6 0.723 43.2 ± 6.9 49.3 ± 10.7 44.8 ± 9.9 0.100
Cardiac index (L/min/m2) 3.16 ± 0.69 3.16 ± 0.92 3.02 ± 0.70 0.709 2.99 ± 0.61 3.31 ± 0.87 3.07 ± 0.89 0.398
LV mass index (g/m2) 88.7 ± 23.7 103.4 ± 37.0 96.6 ± 33.4 0.177 71.2 ± 23.1 83.7 ± 31.3 97.7 ± 36.9 0.030
Data are expressed as mean ± SD, number (percentage), or median (interquartile range)
MR mitral regurgitation and other abbreviations as in Table 1
aAmbulatory 24-h Holter monitoring results were available in 127 of the 161 study patients













significantly with ascending tertiles of SUA in patients
with HCM [30]. During a mean follow-up of 5 years in
that study, elevated uric acid levels independently pre-
dicted adverse outcomes of HCM. However, the associ-
ation between SUA and LVMI remains unclear in
patients with HCM (including obstructive HCM). In the
current investigation, SUA was positively correlated with
LVMI, but not with MWT, in women with obstructive
HCM on univariate analysis. After adjusting for possible
confounding factors which might affect LVMI, SUA was
still independently associated with LVMI in those female
patients. Considering that LVMI assessed by CMR was a
sensitive predictor for HCM-related death [37], the
significant relationship between SUA and LVMI found
in this study may, at least partially, account for the inde-
pendent prognostic values of SUA for adverse outcomes
in patients with HCM [30].
The precise mechanisms underlying the relationship
between SUA and LVMI found in this study are still un-
determined. Several possible pathophysiological mecha-
nisms are proposed as follows. First, it has been reported
that SUA increases tumor necrosis factor-alpha, stimu-
lates mitogen-activated protein kinases, and activates the
renin-angiotensin system, all of which are known to pro-
mote cardiac hypertrophy [38–40]. Second, two previous
studies have indicated that hyperuricemia may lead to
cardiac hypertrophy by increasing arterial stiffness,
which reflects the severity of LV afterload [15, 19]. Third,
SUA is the final product of purine metabolism and cata-
lyzed by xanthine oxidase (XO). SUA levels may reflect
the degree of XO activity and resultant oxidative stress,
which plays an important role in the development of
LVH [41]. Finally, as a common inheritable heart disease,
whether the association between SUA and LVMI ob-
served in our obstructive HCM patients is dependent on
cardiac sarcomere gene mutations or not remains
undefined.
Previous investigations examining the sex-specific rela-
tionship between SUA and LVH yielded conflicting re-
sults. In a cohort of essential hypertension, SUA was
independently associated with LVMI in both male and
female patients [21]. At least three prior studies that per-
formed sex-specific analyses demonstrated a positive as-
sociation of SUA with LVMI and prevalence of LVH in
female hypertensive and CKD patients, but not in their
male counterparts [17, 20, 22]. In contrast, some other
reports suggested that the independent association be-
tween SUA and LVH was only present in males of a gen-
eral population and men with hypertension [14, 16, 18].
To date, this is the first study to explore the sex differ-
ences in the relationship between SUA and cardiac
hypertrophy among obstructive HCM patients. As ex-
pected, SUA levels and LVMI were significantly higher
in men than in women. LVMI increased progressively
from the lower to the upper tertiles of SUA and was
positively correlated with SUA concentrations only in
our female obstructive HCM patients. The positive rela-
tionship between SUA and LVMI in women remained
significant even after adjustment for potential confound-
ing factors, in multivariate linear regression analysis. Al-
though we were unable to elucidate the definite causes
for this gender difference, sex hormones might play a
role in this regard [16, 17, 20, 22]. It is proposed that in-
creased renal clearance of urate related to estrogen in
premenopausal women may account for the lower SUA
levels observed in women than in men [20]. There was a
trend toward lower SUA levels in the premenopausal
women as compared with those of post-menopause in
our study; however, statistical significance was not
reached. In the first study to explore clinical implications
Fig. 1 Left ventricular mass index across sex-specific tertiles of serum uric acid in men and women. p values are for differences across tertiles of
serum uric acid in each gender
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of plasma UA levels on the prognosis of patients with
HCM, Zhu et al. did not analyze by sex and only ad-
justed for sex in multivariate modeling [30]. Further
studies with larger population are required to clarify the
precise reasons for these gender differences regarding
the relationship between SUA and LVH.
It has been proven that allopurinol, via inhibition of
XO, could induce regression of LVH in humans in a
wide spectrum of diseases, including CKD, ischemic
heart disease, and type 2 diabetes mellitus [42–44]. The
significant association between SUA levels and LVMI
observed in our cohort suggests that the use of uric acid
lowering drugs (e.g., allopurinol), on the basis of conven-
tional drugs for HCM and septal reduction therapy, may
theoretically result in an improvement in LV hypertrophy
in patients with obstructive HCM, and subsequent ameli-
oration of cardiovascular outcomes in those patients. Fu-
ture prospective randomized placebo-controlled trials are
warranted to verify that hypothesis.
Of note, contrary to findings of the aforementioned lit-
erature, several other studies have indicated a lack of as-
sociation of SUA with LVH in hypertensive patients
[45–47]. These discrepancies may partly be explained by
methodological differences and heterogeneity of patient
characteristics [45, 46]. Hence, whether the relationship
between SUA and LVH in our female patients with ob-
structive HCM is circumstantial or causal remains to be
clarified.
In accordance with a previous HCM report which
found that LVMI was greater in patients with LVOT
Table 3 Correlations between serum uric acid and clinical parameters by gender
Male (n = 99) Female (n = 62)
Variable r p value r p value
Age (years) −0.03 0.768 0.095 0.463
Body mass index (kg/m2) 0.309 0.002 0.064 0.619
Duration of obstructive HC (months) 0.129 0.203 0.122 0.347
Systolic blood pressure (mmHg) −0.112 0.268 0.05 0.702
Diastolic blood pressure (mmHg) −0.053 0.601 0.013 0.922
Heart rate (beats/min) 0.015 0.881 0.124 0.338
Serum creatinine (μmol/L) 0.136 0.178 0.132 0.307
eGFR (mL/min/1.73 m2) −0.065 0.524 −0.1 0.440
Fasting blood glucose (mmol/L) 0.113 0.264 0.004 0.976
Total cholesterol (mmol/L) 0.16 0.113 0.092 0.476
HDL cholesterol (mmol/L) −0.259 0.010 0.012 0.928
LDL cholesterol (mmol/L) 0.140 0.168 0.171 0.183
Triglycerides (mmol/L) 0.343 0.001 0.129 0.319
hs-CRP (mg/L) 0.198 0.049 0.264 0.038
NT-proBNP (pmol/L) 0.049 0.633 0.162 0.208
HbA1c (%) −0.001 0.988 0.11 0.397
LVOTG at rest (mmHg) −0.149 0.141 −0.095 0.462
LVOTG after provocation (mmHg)a 0.036 0.841 −0.126 0.643
Left atrium diameter (mm) 0.247 0.014 0.277 0.029
LV end-diastolic diameter (mm) −0.072 0.480 −0.07 0.591
Maximum wall thickness (mm) −0.032 0.752 0.075 0.563
LV ejection fraction (%) 0.060 0.558 0.106 0.413
LV mass (g) 0.144 0.155 0.330 0.009
LV end-diastolic volume index (mL/m2) −0.069 0.499 0.013 0.923
LV end-systolic volume index (mL/m2) −0.097 0.341 −0.072 0.577
Stroke volume index (mL/m2) −0.033 0.748 0.072 0.580
Cardiac index (L/min/m2) −0.081 0.426 0.047 0.720
LV mass index (g/m2) 0.112 0.269 0.372 0.003
Abbreviations as in Table 1
aLVOTG was provoked in 50 of the 161 study patients
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obstruction at rest [37], our multivariate analysis showed
that resting LVOT gradient was independently associated
with LVMI in the female subgroup. Our findings provide
a further support to the hypothesis of secondary hyper-
trophy caused by impedance to LVOT in HCM [37].
Study limitations
This study has several limitations. First, this was a cross-
sectional and single-center study with relatively small
sample size. However, by using CMR which has superior
reproducibility, our study population may be large
enough to verify findings in the present study. Second,
we included patients who were taking loop or thiazide
diuretics, which might influence SUA levels. Neverthe-
less, usage of these medications was associated with
SUA neither in univariate nor in multivariate analysis in
this study. Third, all of our subjects enrolled were from
a selected population of Chinese patients with obstruct-
ive HCM, most of whom had severe dyspnea. The find-
ings of our study cannot be extrapolated to other ethnic
groups and those with non-obstructive HCM. Finally, al-
though HCM is a common genetic cardiac disease, no
genetic testing was performed in the current study. Fu-
ture studies with genotyping in this population would
clarify the potential effects of sarcomere mutations on
the relationship between SUA and LVMI.
Conclusions
SUA levels are significantly and independently associated
with LVMI in female patients with obstructive HCM,
but not in males. These findings imply that usage of
urate-lowering drugs (e.g., allopurinol) to regress LVM
may be a new therapeutic target in women with ob-
structive HCM and could provide novel opportunities to
change the natural history of obstructive HCM, espe-
cially in women. Further studies are needed to confirm
that hypothesis.
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Table 4 Multiple linear regression analysis for variables
associated with left ventricular mass index in women
Variable Standardized coefficients (β) p value
Uric acid 0.375 0.002
LVOTG at rest 0.320 0.007
Multiple R = 0.469, R2 = 0.220, abbreviations as in Table 1
Fig. 2 Scatter plots showing the correlations between serum uric acid and left ventricular mass index in each gender
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